

NASDAQ: BSGM



BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals within the rapidly growing \$4.6 billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig is preparing to commercialize its PURE EP™ System. PURE EP™ is a signal acquisition and processing system designed to assist electrophysiologists in making clinical decisions in real-time to help identify areas of tissue that create a heart rhythm disturbance (arrhythmia). PURE EP™ is designed to support catheter ablation cases, working in parallel with existing recording and mapping systems. BioSig's goal is to improve the standards of care in electrophysiology and increase the number of patients who can have their condition successfully treated during the first procedure.

PURE EP™ System





Key Growth Drivers

- 1) Advanced Technology The non-invasive PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. The PURE EP System aims to minimize noise and artifacts, and acquire high-fidelity cardiac signals. Improving cardiac signals may potentially increase the diagnostic value of these signals, thereby possibly improving accuracy and efficiency of the EP studies and ablation procedures. The PURE EP™ System received FDA 510(k) clearance in August
- 2) Market Opportunity Market Research Engine states the global electrophysiology (EP) device market is expected to exceed more than US \$8.5 billion by 2024 and is growing at a compound annual growth rate (CAGR) of 10.6%. The Company also operates within the rapidly emerging field of bioelectronic medicine, estimated at \$3.75 billion in 2017 with projected annual growth of 14.2%.
- KOL Support First successful clinical use of PURE EP™ System was led by two globally recognized leaders: Dr. Andrea Natale of Texas Cardiac Arrhythmia Institute and Prof. John M. Miller of Indiana University. The Company achieved proof of concept validation through UCLA, and performed eighteen pre-clinical studies at Mayo Clinic, MN under the leadership of Samuel J. Asirvatham, M.D., Mayo Clinic's Vice-Chair of Innovation and Medical Director, Electrophysiology Laboratory.

Recent Highlights

- Opened a technology development office in Rochester, Minnesota
- Signed a new licensing agreement with Mayo Clinic
- BioSig's subsidiary NeuroClear Technologies, Inc. raised \$3.7 million in an initial seed round
- Allowed additional foundational **US Patent** for its PURE EP™ System
- Appointed four new senior industry hires: Andrew Ballou Vice President of Investor Relations; Julie Stephenson, BSN, MBA - Senior Director of Clinical Affairs; Olivier Chaudoir - Director of Marketing; Manasi Patwardhan - Director of Strategic Planning
- Added as a member of the Russell 3000® Index
- Appointed Jerome Zeldis, M.D., Ph.D., Samuel E. Navarro, and Martha Pease to Board of Directors
- Received \$4.6 million in cash warrant and option exercises
- Announced that the US Patent & Trademark Office allowed 33 patent claims covering its PURE EP™ System
- Successfully conducted patient cases using PURE EPTM System at Indiana University School of Medicine, Phone: +1-310-620-9320 Texas Cardiac Arrhythmia Institute and Greenville Memorial Hospital
- Appointed Frank J. Quintero and D.A. Wallach to Advisory Board
- Completed private placement for \$8,620,506 in March 2019

Market Snapshot NASDAO: BSGM

TUTOD/TQT DOGITI	
Price (11/05/19)	\$6.63
Average Volume (50 day)	65,316
52-Wk. Range	\$3.55 - \$9.97
Float	16.24M
Shares Outstanding	22.17M
Market Cap	\$147M

BioSig Technologies, Inc. 54 Wilton Road, 2nd Floor Westport, CT 06880 www.biosig.com info@biosigtech.com

Contact:

Kenneth L. Londoner

Phone: +1 (203) 409-5444, x119 klondoner@biosigtech.com

Investor Relations

ir@biosigtech.com

Investment Catalysts

PURE EP™ System


Proprietary Hardware and Software Advanced Signal Processing Capabilities:

- To Improve Signal Clarity Through Reduction of 'Noise' and Artifacts
- To Minimize Need for Repeat Procedures
- To Preserve Important Clinical Information
- To Shorten Procedure Times
- Performing Increase Confidence Complex Ablations



Global EP Market—10.6% Growth from 2016-2024 reaching \$8.5B by 2024

- Global Ablation: 865,000 patients in 2015 to 1,350,000 in 2020.
- Global Procedure Growth: 8.4% annual rate, from 973,220 in 2017 to 1,455 million in 2022
- The FDA (www.fda.gov) presented at the Heart Rhythm Society 2017 and spoke of the importance of technological innovation in the EP field.



Management

Kenneth L. Londoner, MBA, Founder, Chairman, Chief **Executive Officer. Director**

Endicott Management Partners; J & W Seligman & Co; Director: Alliqua

Steve Chaussy, CPA, Chief Financial Officer

Liberski Inc; Anna & Co; Penske Truck Leasing, Ford, Hogg & Cobbe

Natasha Drapeau, Executive Vice President

IG Group Plc, London, UK; Augeous Consulting, Geneva, Switzerland

Barry Keenan, Ph.D, MBA, PMP, VP, Engineering

Engineering; Alfred Mann Foundation for Scientific Research

John Kowalski, VP, Sales

Biosense Webster (Johnson & Johnson)

Andrew Ballou, VP, Investor Relations Janney Montgomery Scott LLC., RBC Capital Markets

Julie Stephenson, Sr. Director of Clinical Affairs

Medtronic, Boston Scientific, Guidant Corporation

Olivier Chaudoir, Director of Marketing

Biosense Webster, DePuy Synthes

Analyst Coverage Laidlaw & Co (UK) Ltd.

ROTH Capital Partners Chardan Capital Markets, LLC.

Proven Team

BioSig is comprised of a stellar cast of a proven management team and a premier Board of Directors with high levels of inside equity ownership.

BioSig brought together leading physicians, executives and engineering experts from leading medical centers of excellence, healthcare programs, Fortune 500 Companies and elite educational institutions including Mayo Clinic, Mount Sinai Medical Center, UCLA, Johnson & Johnson, Nasdaq and Prudential Securities.

Kenneth L. Londoner, Chairman & CEO, has a wealth of knowledge and experience that spans many decades and includes founding, running, and serving as Director to a number of life science companies. Mr. Londoner began his career with J. & W. Seligman & Co., Inc., a leading institutional money management firm where he rose from research analyst to managing \$3.5 billion in mutual funds, pension funds, and international assets. Steve Chaussy. CFO has acted as a consultant for small publicly traded entities with a special emphasis towards SEC reporting and compliance; and served as CFO for a large private distribution and wholesaling company, where he gained international experience.

Their many accomplishments and years of experience of the management team, as well as the Board of Directors and Scientific Advisory Board, is unmatched and provides BioSig a clear advantage in the market.

Investment Highlights

- Member of the Russell 3000® Index
- Successfully Conducted First Patient Cases with PURF FP™
- Stock Appreciation 92% YTD
- Management and Insiders Own Approx. 68% of
- 10-year Strategic Collaboration with Mayo Clinic
- Core competency in Basic Science, Capital Markets and Capital Architecture
- IP Strategy Led by Sherpa Technology Group and Sterne Kessler Goldstein & Fox
- FDA clearance achieved; CE Mark-2020
- Proven Management Team and Board of Directors
- Global and Growing Addressable Market
- Operates Within Rapidly Emerging Field of **Bioelectronic Medicine**
- High-Growth Sector Earns Innovation Premium, Aggressive M&A

Collaborating with Leading EPs from:













Current Cardiac Arrhythmia Epidemic (1 in 18 or 14.4M Americans)

Two of the most prevalent and potentially deadly types of arrhythmias today are Atrial Fibrillation (AF) and Ventricular Tachycardia (VT). Ventricular arrhythmias account for approximately 450,000 sudden deaths per year in the United States alone. Catheter ablation is fast becoming a first line therapy, driving demand for improved technologies. AF is the most common arrhythmia affecting 33.5 million people worldwide, with as many as 6.1 million people in the U.S. now and expected 8-12 million by 2050. AF increases the risk of stroke 4x to 5x and contributes to ~750,000 hospitalizations per year. The direct cost of AF is approximately \$6B annually; adding other indirect costs brings AF total cost to \$26B.

Directors

Donald E. Foley, Director - CEO & Chair: Wilmington Trust; Sr VP, Treas & Dir: ITT Corp; Asst Treas: International Paper Co.

David Weild IV, MBA, Director - Current Chairman & CEO; Weild & Co.; Vice Chairman: NASDAQ; Head of Corporate Finance & Equity Markets: Prudential Securities

Patrick J. Gallagher, MBA, Director - Mg Dir: Laidlaw & Co.; Kinex Pharmaceuticals; Director: Cingulate Therapeutics, BDR Research Group, GC Capital Partners, Kidder Peabody

Jeffrey F. O'Donnell, Sr., Director - Current CEO, Director: Trice Medical; Current Chair: SpectraWave; Director: AdvaMed Accel; Founder: Embrella Cardiovascular (sold to Edwards Lifesciences); CEO: PhotoMedex, Radiance Medical (Cardiovascular Dynamics), Kensey Nash; Medtronic, Nexeon MedSystems, Alfred Mann Institute for Biomedical Sales/Mktg Mngt: Boston Scientific, Guidant, J&J; Former Director: Cardiac Science, Endologix

> Andrew Filler, Director - Current Partner & General Counsel: Sherpa Technology Group, Nanosys; IP Counsel: Previvo Genetics; Board: Aira Technologies. Former: Caliper Life Sciences (sold to Perkin Elmer), Weil, Gotshal & Manges

Jerome Zeldis, M.D., Ph.D, Director - Chief Medical Officer and President of Clinical Research, Medical Affairs Drug Safety, Quality, and Regulatory at Sorrento Therapeutics, Inc.

Samuel E. Navarro, Director - Managing Partner: Gravitas Healthcare, LLC; Former Managing Director and Global Head of Medical Technology Investment Banking: Cowen & Company

Martha Pease, Director - Current Partner and Director at BCG (Boston Consulting Group)